Literature DB >> 8459220

Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44.

G Koopman1, K H Heider, E Horst, G R Adolf, F van den Berg, H Ponta, P Herrlich, S T Pals.   

Abstract

A recently described splice variant of CD44 expressed in metastasizing cell lines of rat tumors, has been shown to confer metastatic potential to nonmetastasizing rat pancreatic carcinoma and sarcoma cell lines. Using antibodies raised against a bacterial fusion protein encoded by variant CD44 sequences, we have explored the expression of variant CD44 glycoproteins on human lymphoid cells and tissues and on non-Hodgkin's lymphomas. Normal lymphohematopoietic cells express barely detectable low levels of variant CD44 glycoproteins, whereas T lymphocytes, upon activation by mitogen or antigen, transiently upregulate expression of specific CD44 variant glycoproteins. The reaction pattern of various antibodies indicates that these CD44 variants contain the domain encoded by exon v6, which is part of the variant that in the rat confers metastatic capability. It is interesting that overexpression of v6 was also found in several aggressive, but not low-grade, non-Hodgkin's lymphomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8459220      PMCID: PMC2190990          DOI: 10.1084/jem.177.4.897

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma.

Authors:  S T Pals; E Horst; G J Ossekoppele; C G Figdor; R J Scheper; C J Meijer
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

2.  A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family.

Authors:  I Stamenkovic; M Amiot; J M Pesando; B Seed
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

3.  Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells.

Authors:  W G Carter; E A Wayner
Journal:  J Biol Chem       Date:  1988-03-25       Impact factor: 5.157

4.  Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies.

Authors:  S Reber; S Matzku; U Günthert; H Ponta; P Herrlich; M Zöller
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

5.  Oncogene jun encodes a sequence-specific trans-activator similar to AP-1.

Authors:  P Angel; E A Allegretto; S T Okino; K Hattori; W J Boyle; T Hunter; M Karin
Journal:  Nature       Date:  1988-03-10       Impact factor: 49.962

6.  CD44 is the principal cell surface receptor for hyaluronate.

Authors:  A Aruffo; I Stamenkovic; M Melnick; C B Underhill; B Seed
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

7.  Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma.

Authors:  S Jalkanen; H Joensuu; P Klemi
Journal:  Blood       Date:  1990-04-01       Impact factor: 22.113

8.  Identification of a widely distributed 90-kDa glycoprotein that is homologous to the Hermes-1 human lymphocyte homing receptor.

Authors:  S T Pals; F Hogervorst; G D Keizer; T Thepen; E Horst; C C Figdor
Journal:  J Immunol       Date:  1989-08-01       Impact factor: 5.422

9.  Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54).

Authors:  E Horst; C J Meijer; T Radaszkiewicz; G J Ossekoppele; J H Van Krieken; S T Pals
Journal:  Leukemia       Date:  1990-08       Impact factor: 11.528

10.  Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types.

Authors:  L J Picker; M Nakache; E C Butcher
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

View more
  67 in total

1.  CD44 variant exons in leukemia and lymphoma.

Authors:  Elif Akisik; Sevil Bavbek; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  Expression of adhesion molecule CD44 on human corneas.

Authors:  S N Zhu; B Nölle; G Duncker
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

3.  Differential expression of CD44(S) and variant isoforms v3, v10 in three-dimensional cultures of mouse melanoma cell lines.

Authors:  Anjali Shiras; Arti Bhosale; Anjali Patekar; Varsha Shepal; Padma Shastry
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 4.  RNA surveillance: molecular approaches in transcript quality control and their implications in clinical diseases.

Authors:  Karen C M Moraes
Journal:  Mol Med       Date:  2009-10-07       Impact factor: 6.354

Review 5.  The normal structure and function of CD44 and its role in neoplasia.

Authors:  R J Sneath; D C Mangham
Journal:  Mol Pathol       Date:  1998-08

6.  Detachment of transformed cells. Role of CD44 variants.

Authors:  C Santos; K Chandler; S Zimmer; P B Fisher; U Gunthert; K W Anderson
Journal:  Cell Biophys       Date:  1995-02

7.  CD44 isoform expression follows two alternative splicing pathways in breast tissue.

Authors:  X Roca; J L Mate; A Ariza; A M Muñoz-Mármol; C von Uexküll-Güldeband; I Pellicer; J J Navas-Palacios; M Isamat
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

8.  Two different functions for CD44 proteins in human myelopoiesis.

Authors:  J Moll; S Khaldoyanidi; J P Sleeman; M Achtnich; I Preuss; H Ponta; P Herrlich
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.

Authors:  M Kryworuckho; F Diaz-Mitoma; A Kumar
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

Review 10.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.